文献速递皮肤肿瘤

造血干细胞移植治疗皮肤T细胞淋巴瘤:多中心倾向评分匹配研究

Haematopoietic stem cell transplant in cutaneous T-cell lymphomas: A multicentre propensity-score matched study.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2025-03-11

基于西班牙原发性皮肤淋巴瘤登记处2848例患者,51例接受造血干细胞移植。移植后完全缓解率70.6%,5年总生存率58.9%,但倾向评分匹配后与未移植组比较未见生存获益,可能与移植前平均已接受6.3线治疗有关。

要点

  • 晚期CTCL患者HSCT后完全缓解率70.6%,5年OS为58.9%。
  • 倾向评分匹配后HSCT组与未HSCT组OS无差异。
  • 移植前平均6.3线治疗可能影响HSCT获益。

核心结论

  • 在RELCP队列中,HSCT患者与未接受HSCT的匹配患者相比未观察到生存获益。

研究设计与样本

  • 回顾性观察性研究,嵌套于西班牙皮肤病与性病学会原发性皮肤淋巴瘤登记处(RELCP),共纳入2848例患者,其中51例接受HSCT。
  • 采用倾向评分匹配(PSM)按诊断、最高疾病分期和诊断时年龄配对HSCT与非HSCT患者,并用Cox回归进行生存分析。

主要发现

  • 56.9%的患者出现复发,39.2%死亡,其中19.6%死于疾病进展,15.7%死于HSCT并发症(主要为移植物抗宿主病和脓毒症)。
  • HSCT后5年总生存率(OS)为58.9%。
  • HSCT组与非HSCT组之间未发现OS差异。

关键数值与推荐

  • HSCT患者移植前平均接受过6.3线治疗。

临床怎么用

  • 晚期原发性CTCL患者接受HSCT前常已多线治疗,真实世界中未见较未移植患者生存优势,需个体化评估。

局限性

  • HSCT组样本量较小(51例),可能影响统计效能。
  • 为回顾性研究,存在选择偏倚可能。
  • 移植前平均6.3线治疗可能反映患者选择偏倚,影响结果解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Advanced cutaneous T-cell lymphomas (CTCL) are rare, generally refractory to therapeutic options, and have a poor prognosis. Haematopoietic stem cell transplantation (HSCT), mainly allogeneic HSCT (allo-HSCT), is considered a potentially curative option in CTCL refractory to other therapies. However, around half of patients relapse, and allo-HSCT is associated with significant adverse events. The available evidence on the usefulness of HSCT in CTCL generally comes from isolated cases and case series with a limited number of patients. OBJECTIVES: Our aim was to evaluate the outcome of patients undergoing HSCT for advanced primary CTCL in Spain in a real-world environment and to compare their survival with that of similar patients who did not receive HSCT. METHODS: We performed a retrospective observational study nested within the Primary Cutaneous Lymphoma Registry (RELCP) of the Spanish Academy of Dermatology and Venereology, collecting data on all patients receiving HSCT. Then, we performed propensity score matching (PSM) to pair HSCT patients with non-HSCT patients, adjusting for diagnosis, highest disease stage and age at diagnosis. We then performed survival analysis by means of Cox regression. RESULTS: Of 2848 patients included in the RELCP, 51 patients underwent HSCT. Thirty-six patients (70.6%) achieved a complete response and seven patients (13.7%) partial response. Relapse was developed by 56.9% of patients, and 39.2% died (19.6% due to disease progression and 15.7% due to HSCT complications, mainly graft-versus-host disease (GVHD) and sepsis). Overall survival (OS) after HSCT at 5 years was 58.9%. No differences in OS were found between HSCT and non-HSCT groups. CONCLUSIONS: We did not observe a survival benefit among HSCT patients compared to non-HSCT patients within the RELCP cohort. This could be due to patients having received a mean of 6.3 lines of treatment before HSCT. Larger studies might help identify subgroups of patients who might benefit from HSCT.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Bejarano L, Grau-Pérez M, Paíno-Román M, et al. Haematopoietic stem cell transplant in cutaneous T-cell lymphomas: A multicentre propensity-score matched study. J Eur Acad Dermatol Venereol. 2025. PMID: 40065681. doi:10.1111/jdv.20638

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。